Khaled Musallam

Dr. Khaled Musallam

International Network of Hematology, London, UK
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in The Lancet
Verified
Journal Article
Closed access
Khaled MusallamKhaled Musallam
Khaled Musallam
HTHani M Tamim
Hani M Tamim
TRToby Richards
Toby Richards
DSDonat R Spahn
Donat R Spahn
FRFrits R Rosendaal
Frits R Rosendaal
FJFaek R Jamali
Faek R Jamali

30 October 2019 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
MCMaria Domenica Cappellini
Maria Domenica Cappellini
Khaled MusallamKhaled Musallam
Khaled Musallam
ATAli T. Taher
Ali T. Taher
Iron deficiency anaemia is a global health concern affecting children, women and the elderly, whilst also being a common comorbidity in multiple medical conditions. The aetiology is variable and attributed to several risk factors decreasing iron intake and absorption or increasing demand and loss, with multiple aetiologies often coexisting in an individual patient. Although presenting symptoms may be nonspecific, there is emerging evidence on the detrimental effects of iron deficiency anaemia on clinical outcomes across several medical conditions. Increased awareness about the consequences and prevalence of iron deficiency anaemia can aid early detection and management. Diagnosis can be easily made by measurement of haemoglobin and serum ferritin levels, whilst in chronic inflammatory conditions, diagnosis may be more challenging and necessitates consideration of higher serum ferritin thresholds and evaluation of transferrin saturation. Oral and intravenous formulations of iron supplementation are available, and several patient and disease‐related factors need to be considered before management decisions are made. This review provides recent updates and guidance on the diagnosis and management of iron deficiency anaemia in multiple clinical settings.

13 June 2017 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
MCMaria Domenica Cappellini
Maria Domenica Cappellini
JCJosep Comin‐Colet
Josep Comin‐Colet
AFAngel de Francisco
Angel de Francisco
ADAxel Dignass
Axel Dignass
WDWolfram Doehner
Wolfram Doehner
OGon behalf of the IRON CORE Group
on behalf of the IRON CORE Group
Iron deficiency, even in the absence of anemia, can be debilitating, and exacerbate any underlying chronic disease, leading to increased morbidity and mortality. Iron deficiency is frequently concomitant with chronic inflammatory disease; however, iron deficiency treatment is often overlooked, partially due to the heterogeneity among clinical practice guidelines. In the absence of consistent guidance across chronic heart failure, chronic kidney disease and inflammatory bowel disease, we provide practical recommendations for iron deficiency to treating physicians: definition, diagnosis, and disease‐specific diagnostic algorithms. These recommendations should facilitate appropriate diagnosis and treatment of iron deficiency to improve quality of life and clinical outcomes.

9 February 2012 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
FPFlora Peyvandi
Flora Peyvandi
RPR. Palla
R. Palla
MMM. Menegatti
M. Menegatti
SSS. M. Siboni
S. M. Siboni
SHS. Halimeh
S. Halimeh
OGON BEHALF OF THE EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN‐RBD) GROUP
ON BEHALF OF THE EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN‐RBD) GROUP
Summary. Background: The European Network of Rare Bleeding Disorders (EN‐RBD) was established to bridge the gap between knowledge and practise in the care of patients with RBDs. Objectives: To explore the relationship between coagulation factor activity level and bleeding severity in patients with RBDs. Patients/Methods: Cross‐sectional study using data from 489 patients registered in the EN‐RBD. Coagulation factor activity levels were retrieved. Clinical bleeding episodes were classified into four categories according to severity. Results: The mean age of patients at data collection was 31 years (range, 7 months to 95 years), with an equal sex distribution. On linear regression analysis, there was a strong association between coagulation factor activity level and clinical bleeding severity for fibrinogen, factor (F) X, FXIII, and combined FV and FVIII deficiencies. A weaker association was present for FV and FVII deficiencies. There was no association between coagulation factor activity level and clinical bleeding severity for FXI. The coagulation factor activity levels that were necessary for patients to remain asymptomatic were: fibrinogen, > 100 mg dL−1; FV, 12 U dL−1; combined FV + VIII, 43 U dL−1; FVII, 25 U dL−1; FX, 56 U dL−1; FXI, 26 U dL−1; FXIII, 31 U dL−1. Moreover, coagulation factor activity levels that corresponded with Grade III bleeding were: undetectable levels for fibrinogen, FV and FXIII, < 15 U dL−1 for combined FV + VIII; < 8 U dL−1 for FVI; < 10 U dL−1 for FX; and < 25 U dL−1 for FXI. Conclusions: There is a heterogeneous association between coagulation factor activity level and clinical bleeding severity in different RBDs. A strong association is only observed in fibrinogen, FX and FXIII deficiencies.

11 March 2010 in Blood
Verified
Journal Article
Open access
PDF file
Ali TaherAli Taher
Ali Taher
Khaled MusallamKhaled Musallam
Khaled Musallam
MKMehran Karimi
Mehran Karimi
AEAmal El-Beshlawy
Amal El-Beshlawy
KBKhawla Belhoul
Khawla Belhoul
MCMaria Domenica Cappellini
Maria Domenica Cappellini
Despite recent advances in understanding the pathophysiologic mechanisms behind the thalassemia intermedia (TI) phenotype, data on the effects of treatment are deficient. To provide such data, we evaluated 584 TI patients for the associations between patient and disease characteristics, treatment received, and the rate of complications. The most common disease-related complications were osteoporosis, extramedullary hematopoeisis (EMH), hypogonadism, and cholelithiasis, followed by thrombosis, pulmonary hypertension (PHT), abnormal liver function, and leg ulcers. Hypothyroidism, heart failure, and diabetes mellitus were less frequently observed. On multivariate analysis, older age and splenectomy were independently associated with an increased risk of most disease-related complications. Transfusion therapy was protective for thrombosis, EMH, PHT, heart failure, cholelithiasis, and leg ulcers. However, transfusion therapy was associated with an increased risk of endocrinopathy. Iron chelation therapy was in turn protective for endocrinopathy and PHT. Hydroxyurea treatment was associated with an increased risk of hypogonadism yet was protective for EMH, PHT, leg ulcers, hypothyroidism, and osteoporosis. Attention should be paid to the impact of age on complications in TI, and the beneficial role of splenectomy deserves revisiting. This study provides evidence that calls for prospective evaluation of the roles of transfusion, iron chelation, and hydroxyurea therapy in TI patients.

31 May 2013 in Haematologica
Verified
Journal Article
Closed access
Khaled MusallamKhaled Musallam
Khaled Musallam
SRS. Rivella
S. Rivella
EVE. Vichinsky
E. Vichinsky
ERE. A. Rachmilewitz
E. A. Rachmilewitz
Non-transfusion-dependent thalassemias include a variety of phenotypes that, unlike patients with beta (β)-thalassemia major, do not require regular transfusion therapy for survival. The most commonly investigated forms are β-thalassemia intermedia, hemoglobin E/β-thalassemia, and α-thalassemia intermedia (hemoglobin H disease). However, transfusion-independence in such patients is not without side effects. Ineffective erythropoiesis and peripheral hemolysis, the hallmarks of disease process, lead to a variety of subsequent pathophysiologies including iron overload and hypercoagulability that ultimately lead to a number of serious clinical morbidities. Thus, prompt and accurate diagnosis of non-transfusion-dependent thalassemia is essential to ensure early intervention. Although several management options are currently available, the need to develop more novel therapeutics is justified by recent advances in our understanding of the mechanisms of disease. Such efforts require wide international collaboration, especially since non-transfusion-dependent thalassemias are no longer bound to low- and middle-income countries but have spread to large multiethnic cities in Europe and the Americas due to continued migration.